论文部分内容阅读
目的:研究Toll样受体2(TLR2)基因单核苷酸多态性(SNP)与肝癌易感性之间的关系。方法:采用病例组与对照组研究,收集211例肝细胞癌(肝癌组)和232例非肝细胞癌(对照组)外周血标本,对TLR2的5个SNP采用多重单碱基延伸SNP分型技术进行基因分型。采用卡方检验比较基因型在病例组与对照组之间分布的差异,采用非条件logistic回归分析多态基因型与肝细胞癌发生危险度的关系。结果:rs3804099、rs3804100基因型在肝癌组与对照组中的分布具有显著性差异(P<0.05)。rs3804099和rs3804100带CT突变杂合子与带TT的野生型纯合子比较,发生HCC的危险性显著降低;经年龄、性别校正后OR值分别为0.493(95%CI:0.331~0.736)和0.509(95%CI:0.342~0.759)(P<0.05)。单倍体TT可显著降低HCC发生的危险(OR 0.524,95%CI:0.394~0.697,P<0.01);相反,单倍体CC可增加肝细胞癌的发生(OR 2.743,95%CI:1.915~3.930,P<0.01)。结论:TLR2基因SNP与肝细胞癌的发生显著相关。
Objective: To investigate the relationship between single nucleotide polymorphism (TLP) of Toll-like receptor 2 (TLR2) gene and susceptibility to hepatocellular carcinoma. Methods: 211 cases of hepatocellular carcinoma (HCC) and 232 cases of non-hepatocellular carcinoma (control group) were collected from the cases and controls. The 5 SNPs of TLR2 were detected by multiplex single base extension SNP Technology for genotyping. The chi-square test was used to compare the distribution of genotypes between case group and control group. The non-conditional logistic regression was used to analyze the relationship between the polymorphism genotypes and the risk of hepatocellular carcinoma. Results: The genotypes of rs3804099 and rs3804100 were significantly different between HCC group and control group (P <0.05). The risk of developing HCC was significantly lower in rs3804099 and rs3804100 heterozygotes with CT mutation than those with TT homozygotes. The odds ratios (ORs) after correction for age and sex were 0.493 (95% CI: 0.331-0.736) and 0.509 % CI: 0.342 ~ 0.759) (P <0.05). Haplotype TT significantly reduced the risk of HCC (OR 0.524, 95% CI: 0.394-0.697, P <0.01). In contrast, haploid CC increased the incidence of hepatocellular carcinoma (OR 2.743, 95% CI 1.915 ~ 3.930, P <0.01). Conclusion: The SNP of TLR2 gene is significantly associated with the occurrence of hepatocellular carcinoma.